Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
The endorsement follows overwhelming support for the share swap preceding the merger,
The conflict is also triggering a widening public health emergency
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The approval comes after a systematic review of published literature
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
Subscribe To Our Newsletter & Stay Updated